It’s Time for CAR T

Every eligible patient should get the opportunity for cure with CAR T-cell therapy.

By 2030 we aim to double the proportion of eligible patients treated with CAR T-cell therapy.

On the site you can learn about CAR T Vision and review the inaugural Vision report and new Vision to Action Blueprint.

Inaugural CAR T Vision report

Outlines the CAR T Vision, its goals, the access challenges it seeks to address, and priority areas for progress, providing a foundation for advocacy and inspiring collective action across stakeholder groups.

CAR T Vision to Action Blueprint

Provides clear, actionable interventions, supported by real-world examples and case studies, that country-level stakeholders can adopt to expand and sustain the delivery of CAR T-cell therapy in the US and Europe.

CAR T Vision Steering Committee

Members of the multidisciplinary global Steering Committee include leading hematologists, patient advocacy and clinical society leaders, technical experts and health economists, with experience from across Europe and North America.

Sharon Anderson

Vice President, Scientific Affairs, Alliance for Regenerative Medicine (ARM)

Miguel-Angel Perales, MD (Co-Chair) 

Past-President (2023-24), American Society for Transplantation and Cellular Therapy (ASTCT) 

Jacqueline Barry

Chief Clinical Officer, Cell and Gene Therapy Catapult (CGT Catapult)

Yelak Biru

Immediate Past-President and Chief Executive Officer, International Myeloma Foundation (IMF)

George Eastwood

Executive Director, Emily Whitehead Foundation

John Gribben, MD, DSc, FRCP, FRCPath, FMed Sci

Barts Cancer Institute, London, and Past President of the European Hematology Association (EHA)

Meghan Gutierrez

Chief Executive Officer, Lymphoma Research Foundation (LRF)

Michael Hudecek, PhD

Professor in Cellular Immunotherapy, Universitätsklinikum Würzburg, Germany; Project Coordinator, T2EVOLVE IMI Consortium

Meagan O’Neill, MS

Executive Director, Association of Cancer Care Centers (ACCC)

David Schmahl 

Chief Executive Officer, Foundation for the Accreditation of Cellular Therapy (FACT)  

Anna Sureda, MD, PhD (Co-Chair)

Clinical Hematologist, Professor and Cell Therapy Researcher

Brian O’Rourke, BSP, Pharm.D., OMM

Independent Healthcare Advisor

Christine Pfaff, RPh, MBA

Director of Clinical Initiatives, Community Oncology Alliance (COA)

Noopur Raje, MD

Director, Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center; Professor of Medicine, Harvard Medical School

Lorna Warwick

Chief Executive Officer, Lymphoma Coalition

Jason Westin, MD, MS, FACP, FASCO

Medical Oncologist, Professor and Cell Therapy Researcher

Endorsements

In developing the CAR T Vision and inaugural report, the Steering Committee consulted with experts and advocates across the healthcare ecosystem to understand how the Vision can support their work and advocacy. As a result, several 12 leading organizations have endorsed the CAR T Vision.

Introduction and overview

CAR T-cell therapy is a potentially curative treatment for patients with blood cancer. However, as outlined in the inaugural report in more detail, currently too many eligible patients are missing out on CAR T-cell therapy and the outcomes it can offer.

Vision for improving patient access to CAR T-cell therapy

We believe every eligible patient should have the opportunity for cure with CAR T-cell therapy. By 2030, we aim to double the proportion of eligible patients treated with CAR T-cell therapy.

An overview of CAR T-cell therapy

CAR T-cell therapy involves removing a person’s T-cells through a process called leukapheresis, where blood is drawn from a vein and T-cells are separated from the blood.

Patient access to CAR T-cell therapy

Despite the life-saving potential of CAR T-cell therapies, a large proportion of eligible patients struggle to access them.

The opportunities for change

To inform the focus and goals of CAR T Vision, the Steering Committee discussed the current challenges to examined access barriers across the patient pathway, and identified three key sets of challenges the CAR T Vision must seek to address.

Case studies

The purpose of these case studies is to provide short, digestible examples of implementable solutions to address common challenges to CAR T-cell therapy.

See all case studies

Vision to Action Blueprint

The CAR T Vision to Action Blueprint provides clear, actionable interventions, supported by real-world examples and case studies, that country-level stakeholders can adopt to address access challenges and enhance the knowledge, capacity, resources, and financial viability needed to expand and sustain the delivery of CAR T-cell therapy in the US and Europe.